• Bromodomain Inhibitor, (+)-JQ1 Workflow Guide

  2026-09-21

  Build reproducible BET pathway experiments with (+)-JQ1, from concentration-response and apoptosis assays to chromatin-focused validation. This guide translates BRD4–RAC1 breast cancer findings into practical assay choices while separating established evidence from exploratory applications in ferroptosis, inflammation, and BRDT biology.

• E. tenella Infection: Microbiome and Metabolome

  2026-09-21

  This study integrates 16S rRNA gene sequencing with LC-MS/MS metabolomics to define how Eimeria tenella infection and treatment alter the chicken cecal ecosystem. Its central contribution is a systems-level view of ethanamizuril, sulfachlorpyridazine, and combination therapy, linking anticoccidial response with microbial and metabolic states.

• Copper–Hexetidine Synergy in Oral Streptococci

  2026-09-20

  Grytten, Scheie, and Giertsen demonstrated that copper and hexetidine interact synergistically against Streptococcus sobrinus and Streptococcus sanguis in broth-based assays. The combination produced fractional inhibitory concentration indices of 0.39–0.40, while growth-curve experiments supported enhanced inhibition at reduced component concentrations, providing a quantitative framework for studying combination antibacterial activity.

• PD 0332991 Workflow for CDK4/6 Research

  2026-09-19

  Build a mechanism-first workflow around PD 0332991 and Palbociclib HCl, from Rb-dependent G1 arrest assays to tumor growth suppression studies. Learn why pancreatic cancer models require paired proliferation, migration, invasion, and pathway readouts rather than viability alone.

• SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors

  2026-09-18

  A 2024 study identifies SNAI1 as a transcriptional hub that promotes epithelial–mesenchymal transition, invasion, and cancer stem cell-like traits in thymic epithelial tumors. Multi-omics and functional experiments connect SNAI1 to PIK3R2, phosphorylated EphA2, and downstream GSK3β/β-catenin signaling, providing a mechanistic framework for therapeutic investigation.

• Bromodomain Inhibitor (+)-JQ1: BET Workflows

  2026-09-18

  Translate BET target engagement into reproducible apoptosis, ferroptosis, inflammation, and BRDT-focused assays with practical dosing and readout guidance. The workflow connects (+)-JQ1 mechanism to the reference study showing that BRD4 inhibition can sensitize diverse cells to erastin-induced ferroptosis.

• HDAC Inhibitors Repress NUT Function in Carcinoma

  2026-09-17

  Shiota et al. developed a dCAS9-based high-throughput reporter screen that identified structurally diverse HDAC inhibitors as repressors of NUT transcriptional activity in NUT carcinoma. Their results connect HDAC inhibition with loss of BRD4–NUT megadomains, oncogenic transcriptional shutdown, tumor-cell differentiation, and improved xenograft control when combined with bromodomain inhibition.

• Azithromycin: An Assay-First Research Framework

  2026-09-17

  Azithromycin is a macrolide antibiotic with applications spanning bacterial infection research, resistance profiling, and exploratory senolytic assays. This assay-first framework explains how to connect ribosomal target engagement with orthogonal cellular readouts while avoiding unsupported cross-domain conclusions.

• X-Gal as a Decision Tool for Molecular Biology

  2026-09-16

  X-Gal is more than a blue-white colony screening reagent: it is an evidence layer for construct triage and reporter validation. This article connects its chemistry and lacZα complementation logic with assay decisions inspired by recent iRhom2 olfaction research.

• Azithromycin: Mechanism, Benchmarks, and Workflows

  2026-09-16

  Azithromycin is a macrolide antibiotic and bacterial protein synthesis inhibitor used in bacterial infection research and antimicrobial resistance studies. Its 23S rRNA binding mechanism is well established, while peptide-specific MIC data, trypanosomosis animal-model findings, and formulation properties require condition-specific interpretation.

• Bestatin (Ubenimex): Reliable Cell Assays

  2026-09-15

  A scenario-based guide to using Bestatin (Ubenimex), SKU A2575, in viability, apoptosis, aminopeptidase activity, and multidrug resistance workflows. It connects biochemical selectivity with practical solvent, dosing, control, and vendor-selection decisions.

• AO/PI Staining Solution for Reliable Cell Counting

  2026-09-14

  AO/PI Staining Solution uses two fluorescent DNA dyes to distinguish membrane-intact and membrane-compromised cells during fluorescence-based cell counting. The dual-stain format supports a fluorescent cell viability assay that can reduce interference from debris and residual red blood cells when validated with the intended instrument.

• Cefepime (BMY-28142) Research Workflows

  2026-09-14

  Build reproducible Cefepime assays for bacterial infection models, central nervous system infection research, and resistance dynamics. This guide combines fresh-solution handling, time-kill design, PKPD-informed sampling, and neurotoxicity-aware troubleshooting.

• Solanesol B8776: Practical Workflow Guide

  2026-09-13

  Solanesol B8776 provides a defined polyisoprenoid alcohol for hydrophobic biochemical, membrane-related, cell-based, and enzyme workflows. Its insolubility in water and ethanol requires DMSO-based preparation, fresh-solution handling, and solvent-matched controls; it is intended for research use only and not for diagnostic or medical applications.

• X-Gal Workflow for Blue-White Colony Screening

  2026-09-12

  Build a more reliable blue-white colony screening workflow with practical guidance on stock preparation, plating, readout, and troubleshooting. This article also shows how X-Gal-based clone triage can support complex recombinant DNA technology projects while keeping functional validation separate from visual selection.

8025 records 1/535 page Next 12345 下5页 Last page